Cassava Sciences Inc. (SAVA) Financial Statements (2024 and earlier)

Company Profile

Business Address 6801 N CAPITAL OF TEXAS HIGHWAY
AUSTIN, TX 78731
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments121,136,000201,015,000233,437,00093,506,00023,081,00019,807,000
Cash and cash equivalents121,136,000201,015,000233,437,00093,506,00023,081,00019,807,000
Receivables962,000     
Prepaid expense759,0001,034,000715,000   
Other current assets287,000  488,000268,000233,000
Other undisclosed current assets6,489,0009,177,00010,330,000   
Total current assets:129,633,000211,226,000244,482,00093,994,00023,349,00020,040,000
Noncurrent Assets
Operating lease, right-of-use asset  122,000210,000295,000 
Property, plant and equipment21,854,00022,864,00020,616,00011,00047,00087,000
Intangible assets, net (including goodwill)176,000622,0001,075,000   
Intangible assets, net (excluding goodwill)176,000622,0001,075,000   
Other noncurrent assets   399,000  12,000
Other undisclosed noncurrent assets     90,000 
Total noncurrent assets:22,030,00023,608,00022,300,000306,000137,00099,000
TOTAL ASSETS:151,663,000234,834,000266,782,00094,300,00023,486,00020,139,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities200,0006,297,00011,806,0001,713,0001,288,000511,000
Employee-related liabilities1,877,00083,00058,00061,000
Accounts payable  4,017,0007,126,000911,000453,000294,000
Accrued liabilities200,0002,280,0002,803,000719,000777,000156,000
Other liabilities385,000492,000631,00094,0009,000 
Other undisclosed current liabilities13,610,000274,00097,00058,00090,000 
Total current liabilities:14,195,0007,063,00012,534,0001,865,0001,387,000511,000
Noncurrent Liabilities
Long-term debt and lease obligation:   139,000235,000  
Liabilities, other than long-term debt  232,000194,000   
Other liabilities  197,000194,000   
Operating lease, liability  35,000139,000235,000 
Other undisclosed noncurrent liabilities    (235,000)  
Total noncurrent liabilities:  232,000333,000235,000  
Total liabilities:14,195,0007,295,00012,867,0002,100,0001,387,000511,000
Equity
Equity, attributable to parent137,468,000227,539,000253,915,00092,200,00022,099,00019,628,000
Common stock42,00042,00040,00035,00022,00017,000
Additional paid in capital518,195,000511,049,000461,181,000267,086,000190,664,000183,567,000
Accumulated deficit(380,769,000)(283,552,000)(207,306,000)(174,921,000)(168,587,000)(163,956,000)
Total equity:137,468,000227,539,000253,915,00092,200,00022,099,00019,628,000
TOTAL LIABILITIES AND EQUITY:151,663,000234,834,000266,782,00094,300,00023,486,00020,139,000

Income Statement (P&L) (USD)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(105,957,000)(80,020,000)(32,868,000)(6,446,000)(4,959,000)(6,662,000)
Operating loss:(105,957,000)(80,020,000)(32,868,000)(6,446,000)(4,959,000)(6,662,000)
Nonoperating income
(Other Nonoperating income)
907,000997,000434,000   
Loss from continuing operations:(105,050,000)(79,023,000)(32,434,000)(6,446,000)(4,959,000)(6,662,000)
Loss before gain (loss) on sale of properties:(32,434,000)(6,446,000)(4,959,000)(6,662,000)
Net loss:(105,050,000)(79,023,000)(32,434,000)(6,446,000)(4,959,000)(6,662,000)
Other undisclosed net income attributable to parent7,833,0002,777,00049,000112,000328,000105,000
Net loss attributable to parent:(97,217,000)(76,246,000)(32,385,000)(6,334,000)(4,631,000)(6,557,000)
Preferred stock dividends and other adjustments      
Net loss available to common stockholders, basic:(97,217,000)(76,246,000)(32,385,000)(6,334,000)(4,631,000)(6,557,000)
Dilutive securities, effect on basic earnings per share      
Other undisclosed net income available to common stockholders, diluted      
Net loss available to common stockholders, diluted:(97,217,000)(76,246,000)(32,385,000)(6,334,000)(4,631,000)(6,557,000)

Comprehensive Income (USD)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(105,050,000)(79,023,000)(32,434,000)(6,446,000)(4,959,000)(6,662,000)
Comprehensive loss, net of tax, attributable to parent:(105,050,000)(79,023,000)(32,434,000)(6,446,000)(4,959,000)(6,662,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: